IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $48.69 Average Target Price from Brokerages
by Teresa Graham · The Cerbat GemIDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seventeen analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $50.4375.
Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group increased their price target on IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday. Wedbush increased their price target on IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, January 22nd. Truist Financial set a $65.00 price target on IDEAYA Biosciences in a report on Monday. Finally, Citigroup increased their price target on IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 19th.
View Our Latest Research Report on IDYA
Insider Buying and Selling at IDEAYA Biosciences
In other IDEAYA Biosciences news, Director Jeffrey Stein purchased 50,000 shares of IDEAYA Biosciences stock in a transaction dated Monday, March 2nd. The shares were purchased at an average cost of $32.96 per share, for a total transaction of $1,648,000.00. Following the completion of the acquisition, the director owned 54,281 shares in the company, valued at $1,789,101.76. This represents a 1,167.95% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 2.50% of the company’s stock.
Institutional Investors Weigh In On IDEAYA Biosciences
Several hedge funds and other institutional investors have recently modified their holdings of IDYA. Rockefeller Capital Management L.P. grew its stake in IDEAYA Biosciences by 1,071.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 3,795 shares of the company’s stock worth $131,000 after purchasing an additional 3,471 shares in the last quarter. Flax Pond Capital LLC bought a new position in IDEAYA Biosciences in the fourth quarter worth approximately $1,353,000. Invesco Ltd. grew its stake in IDEAYA Biosciences by 91.9% in the fourth quarter. Invesco Ltd. now owns 238,314 shares of the company’s stock worth $8,239,000 after purchasing an additional 114,118 shares in the last quarter. XTX Topco Ltd bought a new position in IDEAYA Biosciences in the fourth quarter worth approximately $2,288,000. Finally, Virtus Investment Advisers LLC grew its stake in IDEAYA Biosciences by 53.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 7,819 shares of the company’s stock worth $270,000 after purchasing an additional 2,712 shares in the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.
IDEAYA Biosciences Price Performance
Shares of IDYA stock opened at $32.35 on Friday. IDEAYA Biosciences has a 1 year low of $15.84 and a 1 year high of $39.28. The stock’s 50 day simple moving average is $32.38 and its two-hundred day simple moving average is $32.62. The company has a market cap of $2.84 billion, a PE ratio of -24.69 and a beta of 0.02.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.09. The company had revenue of $10.88 million for the quarter, compared to analysts’ expectations of $5.95 million. During the same quarter last year, the company earned ($1.49) earnings per share. The company’s revenue for the quarter was up 55.7% on a year-over-year basis. Equities research analysts expect that IDEAYA Biosciences will post -3.07 EPS for the current year.
IDEAYA Biosciences News Summary
Here are the key news stories impacting IDEAYA Biosciences this week:
- Positive Sentiment: Positive topline registrational data from the OptimUM-02 Phase 2/3 trial: darovasertib + crizotinib improved median PFS to 6.9 months vs. 3.1 months for control (HR 0.42; 95% CI: 0.30–0.59), meeting the primary endpoint — a result that supports regulatory and commercial upside in metastatic uveal melanoma. PR Newswire
- Positive Sentiment: Market reaction/press coverage pushed the stock sharply higher overnight and in early trading as outlets reported the trial success, creating momentum and heightened investor attention. Investing.com article
- Positive Sentiment: Several firms raised price targets and issued bullish ratings after the data — notable raises include Wedbush to $58 (Outperform), Wells Fargo to $48 (Overweight) and Guggenheim to $54 (Buy) — signaling significant analyst upside expectations. Benzinga The Fly
- Neutral Sentiment: Goldman Sachs raised its price target to $35 but kept a “Neutral” rating — a reminder that not all sell-side desks expect an immediate re-rating into the highest target bands. Benzinga
- Negative Sentiment: Analyst/media caveats and regulatory risk remain — some commentary notes that approval and commercialization are not automatic despite strong PFS, so development and labeling/regulatory paths still carry execution risk. Seeking Alpha
- Negative Sentiment: Profit‑taking and volatility after the sizable overnight rally are likely driving the intraday pullback despite the positive fundamentals — volume is elevated and short-term traders may be locking gains.
About IDEAYA Biosciences
IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.
Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.